TME Pharma
TME Pharma is a clinical-stage company focusing on developing novel therapies for treatment of the most aggressive cancers. We specialize in approaches targeting the tumor microenvironment (TME) in which cancer cells exist. Our unique technology breaks tumor protection barriers against the immune system and blocks tumor repair by neutralizing chemokines in the TME. TME Pharma’s approach works in combination with other forms of treatment to weaken tumor defenses and enable greater therapeutic impact. Our clinical programs in glioblastoma and pancreatic cancer have delivered very promising results and further development is planned.
|
Updated corporate presentation with ESMO 15 Sept 2024 Oral Presentation data showing statistically significant improvement in survival
|
Press Release2024, December 04 07:00 p.m. Correction: TME Pharma announces corporate strategy update and upcoming EUR 2.6 million guaranteed financing with intention to launch public offer open only to shareholders to enable completion of transactions around NOX-A12 and NOX-E36 by June 2025 2024, December 04 08:00 a.m. TME Pharma announces corporate strategy update and upcoming EUR 2.6 million guaranteed financing with intention to launch public offer open only to shareholders to enable completion of transactions around NOX-A12 and NOX-E36 by June 2025 2024, November 23 09:00 a.m. TME Pharma announces poster presentation by U.S. National Cancer Institute on CXCL12 inhibition by NOX-A12 in glioblastoma at 2024 SNO Annual Meeting |
EventsAllinvest Securities Biomed Forum
Aram Mangasarian, Ewelina Staniuk Latest Analyst ReportInvest Securities |